GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgalign Holdings Inc (OTCPK:SRGAQ) » Definitions » Intrinsic Value: Projected FCF

Surgalign Holdings (Surgalign Holdings) Intrinsic Value: Projected FCF : $-32.63 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Surgalign Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-05), Surgalign Holdings's Intrinsic Value: Projected FCF is $-32.63. The stock price of Surgalign Holdings is $0.018. Therefore, Surgalign Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Surgalign Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Surgalign Holdings was 5.76. The lowest was 2.55. And the median was 3.99.

SRGAQ's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.7
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Surgalign Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Surgalign Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgalign Holdings Intrinsic Value: Projected FCF Chart

Surgalign Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.77 -20.20 -76.89 -64.73 -59.27

Surgalign Holdings Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.04 -52.30 -56.50 -59.27 -32.63

Competitive Comparison of Surgalign Holdings's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Surgalign Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgalign Holdings's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgalign Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Surgalign Holdings's Price-to-Projected-FCF falls into.



Surgalign Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Surgalign Holdings's Free Cash Flow(6 year avg) = $-43.17.

Surgalign Holdings's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar23)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-43.16992+-18.935/0.8)/13.320
=-32.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surgalign Holdings  (OTCPK:SRGAQ) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Surgalign Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.018/-32.632249757483
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surgalign Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Surgalign Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgalign Holdings (Surgalign Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Lake Cook Road, Suite 315, Deerfield, IL, USA, 60015
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Executives
Elizabeth A. Lapuma director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Jill Kathleen Frizzley director P.O. BOX 1541, ONE BLUE HILL PLAZA, PEARL RIVER NY 10965
Paolo Amoruso officer: Chief Legal Officer C/O HYPERDYNAMICS CORPORATION, 12012 WICKCHESTER LANE, SUITE 475, HOUSTON TX 77079
David Lyle officer: Chief Financial Officer 6290 SEQUENCE DRIVE, SAN DIEGO CA 92121
Marc E. Mackey officer: EVP, Digital Surgery 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Terry M. Rich officer: President, Global Spine 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
William Scott Durall officer: Chief Commercial Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Christopher Thunander officer: Chief Accounting Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Thomas Mceachin director 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Enrico Sangiorgio officer: EVP, International 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Stuart F. Simpson director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Pawel Lewicki director 296 WOODWARD BLVD., TULSA OK 74114
Jeffrey C Lightcap director 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019